NEW YORK (GenomeWeb) — Horizon Discovery Group said today that it has entered into an original equipment manufacturer agreement with CareDx.

Under the agreement, Horizon will supply cell-free DNA-based molecular reference standards for inclusion in CareDx's cfDNA testing workflows for the monitoring of transplanted organ rejection. Financial details of the agreement were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.